Abstract

Artificial intelligence (AI) technologies continue to play significant roles during the Coronavirus 2019 (COVID-19) pandemic in the world. However, health is an area where the rules are stringent and inflexible. This can be justified because it deals with human life. Nevertheless, at the same time, a large number of tests, certifications, and panels will lead to innovations in AI for healthcare that are longer, more complex, and difficult to incorporate into real-world applications. Indonesia has a lot of AI research, which is challenging to commercialize in medicine. These researches are not yet effective due to several limitations in terms of (i) the readiness of a skilled workforce to develop and use AI, (ii) the readiness of regulations that regulate the ethics of using and utilizing responsibly, (iii) the readiness of computational infrastructure and supporting data for AI modeling, and (iv) readiness industry and the public sector in adopting AI innovations. In pandemic outbreak COVID-19, AI technology should help the medical industry more significantly, caused by such limitations, and it has not yet been impactful against COVID-19 in Indonesia. In the future, AI technology exists as a complementary facility to increase the productivity of medical personnel and acts as a disease prevention facility.